- NCIt
- C3862
Loading cancer entity…
Loading cancer entity…
Clinical trials
104 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (23)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03387553 | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | completed | Early Phase 1 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05501704 | ETHAN - ET for Male BC | recruiting | Phase 2 | 60 | Jose Pablo LeoneOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07558343 |
| Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2(MATADOR2) |
| not yet recruiting |
| N/A |
| 120 |
| Institut Claudius RegaudOTHER |
| 1 |
| Aug 19, 2026 |
| clinicaltrials |
| NCT00770809 | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | completed | Phase 3 | 305 | National Cancer Institute (NCI)NIH | 2 | Aug 12, 2026 | clinicaltrials |
| NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | completed | Phase 2 | 454 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT07455110 | EORTC Quality of Life Measurement in Males With Breast Cancer(BR Male) | completed | — | 65 | Helios University Hospital WuppertalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | recruiting | N/A | 800 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03384914 | Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer | active not recruiting | Phase 2 | 119 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01349959 | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2025 | clinicaltrials |
| NCT03800355 | Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk | completed | — | 777 | Spanish Breast Cancer Research GroupOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05156606 | Testosterone & Tamoxifen Trial(T&T) | terminated | N/A | 5 | University Medical Center GroningenOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01706432 | Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer | completed | — | 4 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT01703520 | Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021). | completed | — | 575,216 | Organon and CoINDUSTRY | 0 | May 10, 2024 | clinicaltrials |
| NCT00096434 | Sorafenib in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2024 | clinicaltrials |
| NCT01931709 | FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer | terminated | N/A | 35 | University of WashingtonOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03018080 | Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer(PePPy) | completed | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | terminated | Phase 2 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT00470301 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2021 | clinicaltrials |
| NCT03295695 | PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT00343109 | Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer | completed | Phase 2 | 38 | University of WashingtonOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT01355393 | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01720602 | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | completed | N/A | 15 | University of WashingtonOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01783756 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | completed | Phase 1 / Phase 2 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01084057 | Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 | 56 | City of Hope Medical CenterOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01869764 | Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer | completed | Phase 2 | 57 | Wake Forest University Health SciencesOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01153672 | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | completed | N/A | 8 | University of WashingtonOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT00513695 | Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | completed | Phase 2 | 68 | University of WashingtonOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01372579 | Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT00063934 | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02580448 | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)(CLARITY-01) | completed | Phase 1 / Phase 2 | 175 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT00425672 | ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment | completed | Phase 1 / Phase 2 | 15 | University of WashingtonOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT01632332 | Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer | completed | Phase 1 | 22 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01638247 | Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients(MALE) | completed | Phase 3 | 56 | GBG Forschungs GmbHOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01493310 | Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer | completed | Phase 1 | 9 | University of ChicagoOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT02046421 | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 31 | University of ChicagoOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT01394211 | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | terminated | Phase 2 | 2 | University of ArizonaOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT02060253 | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT00699491 | Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 13, 2018 | clinicaltrials |
| NCT01928186 | FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer | completed | N/A | 28 | University of WashingtonOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT01042535 | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01624441 | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00821964 | Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer | completed | Phase 2 | 15 | University of WashingtonOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials